Type 2 Diabetes(T2D)is a growing global health issue,often aggravated by excessive sugar intake.Chronic high-sucrose diets contribute to insulin resistance,oxidative stress,and pancreatic dysfunction,worsening metabol...Type 2 Diabetes(T2D)is a growing global health issue,often aggravated by excessive sugar intake.Chronic high-sucrose diets contribute to insulin resistance,oxidative stress,and pancreatic dysfunction,worsening metabolic health.Sodium-glucose co-transporter 2(SGLT2)inhibitors,like empagliflozin,show potential in improving glycemic control and metabolic parameters,but their effects on pancreatic efficiency in sugar-induced T2D are not well understood.This study aimed to explore the effects of empagliflozin on metabolic and pancreatic protection in a high-sucrose diet-induced T2D model.Male Wistar rats were divided into four groups:normal,normal-treated,diabetic,and diabetic-treated(n=8 per group).Diabetes was induced with a 35%sucrose solution for 8 weeks,followed by a low-dose streptozotocin(STZ)injection.Treated groups received empagliflozin(15 mg/kg/day)for the duration.Biochemical markers,including fasting blood sugar(FBS),lipid profile,insulin levels,and oxidative stress markers,were measured.Insulin resistance(HOMA-IR)and pancreatic function(HOMA-B)were assessed.Histological analysis of pancreatic tissues was performed.The high-sucrose diet increased FBS,insulin resistance,and oxidative stress,while decreasing pancreatic function and islet diameter.Empagliflozin treatment lowered FBS(p=0.001),improved insulin sensitivity(p=0.001),reduced triglycerides(p=0.001),and LDL(p=0.05).It also enhanced antioxidant enzymes,reduced lipid peroxidation(MDA,p=0.001),and preserved pancreatic islet structure(p=0.001).A high-sucrose diet negatively affects metabolic health and pancreatic function.Empagliflozin mitigates these effects by improving metabolism,reducing oxidative stress,and preserving pancreatic integrity,suggesting its potential as a therapeutic agent in diabetes related to excessive sugar consumption.展开更多
文摘Type 2 Diabetes(T2D)is a growing global health issue,often aggravated by excessive sugar intake.Chronic high-sucrose diets contribute to insulin resistance,oxidative stress,and pancreatic dysfunction,worsening metabolic health.Sodium-glucose co-transporter 2(SGLT2)inhibitors,like empagliflozin,show potential in improving glycemic control and metabolic parameters,but their effects on pancreatic efficiency in sugar-induced T2D are not well understood.This study aimed to explore the effects of empagliflozin on metabolic and pancreatic protection in a high-sucrose diet-induced T2D model.Male Wistar rats were divided into four groups:normal,normal-treated,diabetic,and diabetic-treated(n=8 per group).Diabetes was induced with a 35%sucrose solution for 8 weeks,followed by a low-dose streptozotocin(STZ)injection.Treated groups received empagliflozin(15 mg/kg/day)for the duration.Biochemical markers,including fasting blood sugar(FBS),lipid profile,insulin levels,and oxidative stress markers,were measured.Insulin resistance(HOMA-IR)and pancreatic function(HOMA-B)were assessed.Histological analysis of pancreatic tissues was performed.The high-sucrose diet increased FBS,insulin resistance,and oxidative stress,while decreasing pancreatic function and islet diameter.Empagliflozin treatment lowered FBS(p=0.001),improved insulin sensitivity(p=0.001),reduced triglycerides(p=0.001),and LDL(p=0.05).It also enhanced antioxidant enzymes,reduced lipid peroxidation(MDA,p=0.001),and preserved pancreatic islet structure(p=0.001).A high-sucrose diet negatively affects metabolic health and pancreatic function.Empagliflozin mitigates these effects by improving metabolism,reducing oxidative stress,and preserving pancreatic integrity,suggesting its potential as a therapeutic agent in diabetes related to excessive sugar consumption.
